Navigation Links
Heritage Pharmaceuticals Inc. Signs Exclusive Development Supply & Distribution Agreement with Dexcel Ltd.
Date:8/5/2014

EATONTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") has signed an Exclusive Development, Supply & Distribution Agreement with Dexcel Ltd. ("Dexcel") for an Extended Release ANDA drug product. Dexcel will be responsible for the development, registration and manufacturing of the product, and Heritage Pharmaceuticals will be responsible for marketing and distribution in the U.S. The product generates generic annual U.S. sales of approximately $60 million, per IMS Health. Financial terms of the agreement were not disclosed.

Jeffrey A. Glazer, Heritage's Vice Chairman and CEO stated, "I am pleased to expand our relationship with Dexcel for high barrier, technology driven pharmaceutical products. This agreement builds upon our platform of pipeline expansion through strategic alliance and will complement our organic product assets as we continue to offer a broad portfolio of value driven medicine to the U.S. consumer."

About Heritage

Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management. Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.

About Dexcel Pharma

Dexcel Pharma is a private international specialty pharmaceutical group, de
'/>"/>

SOURCE Heritage Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Heritage Provider Network, UCLA and Open mHealth announce the launch of $100,000 mobile apps health prize challenge
2. Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Prize Announced
3. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
4. Heritage Pharma Announces The Return Of Tetracycline HCI Capsules
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... BioNano Genomics announced today achievement of a major milestone ... at 30X depth, sufficient for a genome map, in 24 ... and demonstrated for the IrysChip TM V2, the high-throughput ... will be rolled out to BioNano,s collaborators and customers over ... at the American Society for Human Genetics (ASHG) 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Inhibitor-, SOUTH SAN FRANCISCO, Calif., Jan. 7 ... has initiated a phase 1/2 trial,of XL184 in patients ... disease while on a regimen containing erlotinib., XL184 ... RET and,VEGFR receptor tyrosine kinases. In the initial phase ...
... scientists today,report that the genetic variant on chromosome ... of heart attack is also associated with up ... (AAA) and intracranial,aneurysm (IA). This is the first ... condition. The paper, entitled ,The same sequence,variant on ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Leading provider ... and a look back on its early usage of the Internet to help patients find ... ... industry news, data analysis, and proprietary market research for clinical trials professionals and patients, turns ...
... , , , ... , , CHICAGO, Aug. 27 Chicago ... provide housing and support for people living with HIV and AIDS, will ... President Bill Clinton as the keynote speaker. , , ...
... STAMFORD, Conn., Aug. 27 American children miss more ... other two diseases combined.(1) As parents help their kids prepare for ... a lifetime of good oral health with the new Philips Sonicare ... Sonicare For Kids is specially designed to support kids, needs at ...
... , , , ... announced today that it has entered into an agreement with Pfizer ... cell lung cancer (NSCLC) tumors for the presence of gene rearrangements. ... cancer-causing genes implicated in the progress of many cancers. To ...
... similar to those with deceased donor transplant organs, study ... with kidney disease may do just as well receiving ... a deceased donor, new research has found. , Researchers ... patients who had either received a kidney transplant from ...
... , , ... Technologies, Inc., a leading nationwide provider of information technology solutions ... State Health Plan ("VSHP"), a wholly-owned subsidiary of BlueCross Blue ... use Sandata,s IntegriCare 2.0 to manage electronic visit verification of ...
Cached Medicine News:Health News:CenterWatch Celebrates 15-Year Milestone as Leading Information Provider for the Clinical Trials Industry 2Health News:President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices 2
... on the market today. The horseshoe evaporator ... contoured drain channels away moisture for continual ... coated with a tough, baked-on epoxy paint ... reversible. The interior of the refrigerator is ...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... a basic laboratory system for pH and ... be obtained when used with a temperature ... Fast and easy one and two-point calibration ... buffers (pH 1.68, 4.00, 7.00, 10.01 and ...
Medicine Products: